Published By : 05 Apr 2016 | Published By : QYRESEARCH
The testosterone replacement therapy refers to administering testosterone when testes do not produce adequate amount of testosterone due to damage, injury, or absence. The testosterone replacement therapy has gained popularity in the last decade with high penetration in surgery market. Depending on the type of product, the testosterone replacement therapy market is segmented into three categories: gel, patches and other. The growing awareness of testosterone treatment and hypogonadism, along with rapidly growing geriatric population with high disposable income will drive this market. This market is anticipated to expand with strong promotional activities from pharmaceutical companies to educate patients and physicians.
Some of the prominent players in the testosterone replacement therapy market are Columbia Laboratories Inc., Endo Pharmaceuticals Inc., Abbott Laboratories, Auxilium Pharmaceuticals Inc., Glaxo Smith Kline plc, Eli Lilly and Company, Kyowa Hakko Kirin Co. Ltd, Bayer Schering Pharma AG, ProStrakan Group PLC., Watson Pharmaceuticals Inc., Trimel BioPharma SRL, Slate Pharmaceuticals Inc., Acrux Limited, and others
Study Reveals Patients Not Receiving Testosterone Therapy Likely to Suffer from Adverse Cardiac Events
According to a recent study conducted by the Intermountain Medical Centre Heart Institute in Salt Lake City, testosterone therapy reduces the risk of major life threatening cardiovascular events including heart attack, stroke, and death across older men suffering from low testosterone levels and coronary artery diseases. The study revealed that the patients who received the therapy showed better results compared to patients who did not. Patients not receiving the testosterone therapy are more likely to suffer from an adverse event. With the growing prevalence of cardiac disorders, the testosterone therapy is anticipated to be widely preferred by patients and doctors alike.